According to an 8-K filing, Myriad Genetics entered into a credit agreement by and among Myriad, as borrower, and JPMorgan Chase, as administrative agent and collateral agent, Wells Fargo as syndication agent and U.S. Bank, PNC Bank, Fifth Third Bank, Zions First National and Silicon Valley Bank, as co-documentation agents, providing for a senior secured revolving credit facility in an aggregate principal amount of up to $300 million which amount will include $10 million sublimits for swingline loans and letters of credit.

Pursuant to the facility, Myriad borrowed revolving loans in an aggregate principal amount of $205 million. The facility matures on December 23, 2021.

The proceeds of the facility were use to refinance in full the obligations under the Myriad term loan facility entered into on August 31, 2016, to pay any fees and related expenses and for working capital and general corporate purposes.

The facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries, and each such domestic subsidiary of Myriad has guaranteed the repayment of the facility.